Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer

por Louvet, C., André, T., Gamelin, E., Hebbar, M., Mabro, M., Bennamoun, M., Rassam, H., de Gramont, A.
Publicado 2010

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma

por Santos, C D, Tijeras-Raballand, A, Serova, M, Sebbagh, S, Slimane, K, Faivre, S, de Gramont, A, Raymond, E
Publicado 2015

A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients

por Mabro, M, Artru, P, André, T, Flesch, M, Maindrault-Goebel, F, Landi, B, Lledo, G, Plantade, A, Louvet, C, de Gramont, A
Publicado 2006

MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF(wt) metastatic colorec...

por Tabernero, J., Grothey, A., Arnold, D., de Gramont, A., Ducreux, M., O’Dwyer, P., Tahiri, A., Gilberg, F., Irahara, N., Schmoll, H.-J., Van Cutsem, E.
Publicado 2022

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCEN...

por Taieb, J., Shi, Q., Pederson, L., Alberts, S., Wolmark, N., Van Cutsem, E., de Gramont, A., Kerr, R., Grothey, A., Lonardi, S., Yoshino, T., Yothers, G., Sinicrope, F.A., Zaanan, A., André, T.
Publicado 2019

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group

por Bleiberg, H., Decoster, G., de Gramont, A., Rougier, P., Sobrero, A., Benson, A., Chibaudel, B., Douillard, J. Y., Eng, C., Fuchs, C., Fujii, M., Labianca, R., Larsen, A. K., Mitchell, E., Schmoll, H. J., Sprumont, D., Zalcberg, J.
Publicado 2017